Replies to post #74084 on PharmaCyte Biotech Inc (PMCB)

[concordia]

We all feel that the suggested changes we received from the FDA should not take long to make
February 13, 2017

6 months later no updates.

[JimboPMCB]

All a Hoax. The technology has a good marketing story.

[rudygerner]

Partnership and IND coming 4Q17: https://www.facebook.com/austrianova/photos/a.806632359368640.1073741832.747212361977307/1616942508337617/?type=3&theater

Next step is to file the IND: http://ir.pharmacytebiotech.com/press-releases/detail/133/pharmacyte-biotech-moves-closer-to-filing-ind-with-naming

"Other highly positive news provided by Mr. Waggoner concerning the pre-IND meeting with the FDA included:

- agreement with the FDA that PharmaCyte is on the “right track” in its development program;

-agreement with the FDA on the cell line that will be used in the clinical trial;

-agreement with the FDA on the patient population to be studied in the clinical trial;

-agreement with the FDA on the secondary endpoints of the clinical trial, except that PFS will be added to the list of secondary endpoints if the trial becomes a pivotal trial;

-agreement with the FDA on the number of patients needed to comprise an adequate safety database for a Biologics Licensing Application for CypCaps™;

-agreement that the FDA believes CypCaps™ is a drug/device combination product;

-agreement with the FDA that it will assist PharmaCyte in its development program;

-agreement with the FDA that the next step for PharmaCyte is to submit an IND.

IND coming 4Q17.